ATE398461T1 - Impstoffe zur transkutanen immunisierung gegen reisediarrhö - Google Patents

Impstoffe zur transkutanen immunisierung gegen reisediarrhö

Info

Publication number
ATE398461T1
ATE398461T1 AT02718962T AT02718962T ATE398461T1 AT E398461 T1 ATE398461 T1 AT E398461T1 AT 02718962 T AT02718962 T AT 02718962T AT 02718962 T AT02718962 T AT 02718962T AT E398461 T1 ATE398461 T1 AT E398461T1
Authority
AT
Austria
Prior art keywords
vaccines
transcutaneous immunization
etec
immunization against
against travel
Prior art date
Application number
AT02718962T
Other languages
English (en)
Inventor
Gregory Glenn
Frederick Cassels
Original Assignee
Us Gov Sec Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27500924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE398461(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Sec Army filed Critical Us Gov Sec Army
Application granted granted Critical
Publication of ATE398461T1 publication Critical patent/ATE398461T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT02718962T 2001-02-13 2002-02-13 Impstoffe zur transkutanen immunisierung gegen reisediarrhö ATE398461T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26801601P 2001-02-13 2001-02-13
US30411001P 2001-07-11 2001-07-11
US31048301P 2001-08-08 2001-08-08
US31044701P 2001-08-08 2001-08-08

Publications (1)

Publication Number Publication Date
ATE398461T1 true ATE398461T1 (de) 2008-07-15

Family

ID=27500924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02718962T ATE398461T1 (de) 2001-02-13 2002-02-13 Impstoffe zur transkutanen immunisierung gegen reisediarrhö

Country Status (12)

Country Link
US (1) US7527802B2 (de)
EP (1) EP1372708B1 (de)
JP (2) JP2005504002A (de)
AT (1) ATE398461T1 (de)
AU (1) AU2002250071B2 (de)
CA (1) CA2437899C (de)
CY (1) CY1111030T1 (de)
DE (1) DE60227157D1 (de)
DK (1) DK1372708T3 (de)
ES (1) ES2310201T3 (de)
PT (1) PT1372708E (de)
WO (1) WO2002064162A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CA2437899C (en) * 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
US20040109869A1 (en) * 2001-03-19 2004-06-10 Iomai Corporation Transcutaneous immunostimulation
CA2477273A1 (en) * 2002-02-25 2003-09-18 U.S. Army Medical Research And Materiel Command Method of making cs6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält
WO2005113005A2 (en) * 2004-05-20 2005-12-01 The United States Of America As Represented By The Secretary Of The Army Transcutaneous and/or transdermal transport of materials
EP1773385A4 (de) * 2004-06-15 2009-01-14 Iomai Corp HAUTIMMUNISIERUNG MIT LT-Sta-FUSIONSPROTEINEN
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2006039659A1 (en) * 2004-10-02 2006-04-13 Sri International Bioadhesive delivery system for transmucosal delivery of beneficial agents
EP1855718B1 (de) * 2005-01-11 2016-10-12 The United States of America as represented by The Secretary of The Navy Donor Strang komplementierte Adhesine als immunogen gegen Escherichia coli.
FR2887457B1 (fr) * 2005-06-23 2007-10-05 Fond Bettencourt Schueller Vaccination par ciblage transcutane
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
WO2007117339A2 (en) 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
WO2007089205A1 (en) * 2006-02-01 2007-08-09 Sbl Vaccin Ab Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
FR2924350B1 (fr) * 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339551B2 (en) 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O
US9169327B2 (en) * 2008-03-12 2015-10-27 Rowan University Targeting of podoplanin with lectin for use in the prevention and treatment of cancer
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
US20110159035A1 (en) 2008-08-01 2011-06-30 Masahiro Goto S/o type transdermal immunizing agent
EP2355846A4 (de) * 2008-09-03 2013-06-19 Univ Michigan State Immunogenes wärmestabiles escherichia coli-enterotoxin
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
US20100286600A1 (en) * 2009-05-08 2010-11-11 Bommannan D Bommi Transdermal patch device
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
WO2010143689A1 (ja) * 2009-06-10 2010-12-16 久光製薬株式会社 マイクロニードルデバイス
EP2442826B1 (de) 2009-06-15 2015-07-08 National University of Singapore Influenzaimpfstoff, zusammensetzung und seine verwendung
EP2464341B1 (de) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunmodulatorische zusammensetzungen mit einer polymermatrix und einer ölphase
US20120269842A1 (en) * 2009-10-09 2012-10-25 South Dakota State University Enterotoxigenic e. coli fusion protein vaccines
EP2556151A1 (de) 2010-04-07 2013-02-13 Novartis AG Verfahren zur erzeugung von virusähnlichen parvovirus-b19-partikeln
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
CN103154242B (zh) 2010-07-06 2015-09-30 诺华股份有限公司 诺如病毒衍生的免疫原性组合物和方法
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
EP2750701B1 (de) 2011-09-12 2015-10-21 Scandinavian Biopharma Holding AB Verfahren zur erhöhung der etec-cs6-antigenpräsentation auf zelloberflächen und dadurch gewinnbare produkte
CN103930436A (zh) 2011-09-14 2014-07-16 诺华股份有限公司 大肠杆菌疫苗组合
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
EP3608401A1 (de) 2012-07-05 2020-02-12 Ohio State Innovation Foundation Zusammensetzungen und verfahren in zusammenhang mit viralen impfstoffen
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
EP2897638A1 (de) 2012-09-24 2015-07-29 Montana State University-Bozeman Rekombinanter lactococcus lactis zur expression des escherichia coli-kolonisationsfaktor-antigens i (cfa/i) fimbriae und verfahren zu deren verwendung
JP6403680B2 (ja) * 2012-11-19 2018-10-10 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ 複数の毒素原性大腸菌線毛サブユニットを含む組み換えポリペプチド構築物
TR201809679T4 (tr) * 2012-12-28 2018-07-23 Cellestis Ltd Hücre aracılı bir immün yanıt tahlili.
WO2014138748A1 (en) * 2013-03-08 2014-09-12 Research Institute At Nationwide Children's Hospital Transcutaneous dosage formulation
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
SG11201604805XA (en) 2013-12-16 2016-07-28 Massachusetts Inst Technology Fortified micronutrient salt formulations
JP2017507165A (ja) * 2013-12-16 2017-03-16 マサチューセッツ インスティテュート オブ テクノロジー マイクロモールド成形された、または３次元印刷されたパルス放出ワクチン製剤
HUE053624T2 (hu) 2014-11-07 2021-07-28 Sublimity Therapeutics Ltd Ciklosporint tartalmazó készítmények
WO2016149482A2 (en) * 2015-03-17 2016-09-22 Vanderbilt University Cs21 and lnga protein vaccines
US11439703B2 (en) * 2015-07-31 2022-09-13 ELANCO US, Inc. Enhanced immune response in porcine species
EP3344290A4 (de) 2015-08-31 2019-02-27 Technovax, Inc. Impfstoff basierend auf virenähnlichen partikeln des humanen respiratorischen synzytial-virus (hrsv)
WO2017094793A1 (ja) * 2015-11-30 2017-06-08 出光興産株式会社 免疫原性が増強されたワクチン抗原
CN106267191A (zh) * 2016-09-03 2017-01-04 山西纳安生物科技有限公司 纳米抗体生物药透皮给药制剂系统及制备方法和应用
US20200215187A1 (en) * 2017-07-24 2020-07-09 Bioserentach Co., Ltd. Vaccine adjuvant and microneedle preparation
CA3178260A1 (en) 2020-05-13 2021-11-18 Massachusetts Institute Of Technology Compositions of polymeric microdevices and their use in cancer immunotherapy

Family Cites Families (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US3837340A (en) 1971-10-20 1974-09-24 Lilly Co Eli Device for administering immunication against virus
US3948263A (en) * 1974-08-14 1976-04-06 Minnesota Mining And Manufacturing Company Ballistic animal implant
US3982536A (en) 1974-11-15 1976-09-28 Minnesota Mining And Manufacturing Company Ballistic inoculation of animals and projectile therefor
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4220584A (en) 1978-01-30 1980-09-02 Merck & Co., Inc. E. coli enterotoxin vaccine for veterinary and human use
US4285931A (en) * 1978-01-30 1981-08-25 Merck & Co., Inc. E. coli enterotoxin vaccine for veterinary and human use
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4455142A (en) * 1980-07-07 1984-06-19 Alza Corporation Method of coadministering an antigen and an immunopotentiator
US4761372A (en) 1981-01-12 1988-08-02 New York University Mutant enterotoxin of E. coli
US4411888A (en) 1981-06-22 1983-10-25 The University Of Rochester Composition of a novel immunogen for protection against diarrheal disease caused by enterotoxigenic Escherichia coli
US4484923A (en) 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4587044A (en) * 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US4725271A (en) * 1983-10-17 1988-02-16 Enquay Pharmaceutical Associates Synthetic resin matrix drug storage and topical drug delivery dressing for veterinary usage
US4743588A (en) * 1984-06-13 1988-05-10 Allergan Pharmaceuticals, Inc. Compositions and methods of enhancing transdermal and transmembrane penetration systemic agents
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US5308835A (en) * 1984-07-09 1994-05-03 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
US5008111A (en) * 1984-10-11 1991-04-16 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4692462A (en) 1985-03-18 1987-09-08 Menley & James Laboratories, Ltd. Compositions and method of controlling transdermal penetration of topical and systemic agents
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4732892A (en) * 1985-07-12 1988-03-22 American Home Products Corporation L-α-amino acids as transdermal penetration enhancers
DE3527893A1 (de) 1985-08-03 1987-02-05 Merck Patent Gmbh Epikutan-testpflaster
GB2191941B (en) 1985-08-27 1990-03-14 Glyzinc Pharma Ltd Zinc glycerolate complex and additions for pharmaceutical applications
US4970206A (en) 1985-11-29 1990-11-13 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) * 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US4764381A (en) 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5270346A (en) 1986-01-31 1993-12-14 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5142044A (en) 1986-04-23 1992-08-25 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5041439A (en) 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US5326790A (en) 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US4876249A (en) 1987-01-12 1989-10-24 Rajadhyaksha Vithal J Compositions and method comprising heterocyclic compounds containing two heteroatoms
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
US5049387A (en) 1987-03-09 1991-09-17 Alza Corporation Inducing skin tolerance to a sensitizing drug
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US5045317A (en) 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
JP2594441B2 (ja) * 1987-07-16 1997-03-26 日本鋳造株式会社 快削性高温低熱膨張鋳造合金の製造方法
JP2520262B2 (ja) 1987-08-21 1996-07-31 春幸 川原 パツチテスト材料
US5059189A (en) 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
AU614092B2 (en) * 1987-09-11 1991-08-22 Paul Max Grinwald Improved method and apparatus for enhanced drug permeation of skin
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
US4917895A (en) * 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5234959A (en) 1988-04-08 1993-08-10 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5472946A (en) 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US5082866A (en) * 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US5164406A (en) 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
US4960771A (en) 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US4892737A (en) * 1988-09-22 1990-01-09 University Of Florida Composition and method for enhancing permeability of topical drugs
US5032402A (en) 1988-10-27 1991-07-16 The University Of Kentucky Research Foundation 3-hydroxy-N-methylpyrrolidone and use as transdermal enhancer
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
LU87410A1 (fr) 1988-12-20 1990-07-10 Cird Composition cosmetique ou pharmaceutique contenant des microspheres de polymeres ou de corps gras chargees d'au moins un produit actif
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
IE62662B1 (en) 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
KR0157428B1 (ko) * 1989-02-17 1998-11-16 알렌 불룸 비 전달용 지질부형제와 그 사용법
US5534260A (en) 1989-02-23 1996-07-09 University Of Utah Percutaneous drug delivery system
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5411738A (en) * 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5162315A (en) 1989-05-08 1992-11-10 Rajadhyaksha Vithal J Penetration enhancers
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US6413523B1 (en) 1989-06-02 2002-07-02 The United States Of America As Represented By The Secretary Of The Navy Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US4956171A (en) 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
DE3924393A1 (de) 1989-07-24 1991-01-31 Roehm Gmbh Wasserloeslicher druckempfindlicher hauthaftkleber, dessen verwendung und damit ausgeruestete mittel
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
EP0429842B1 (de) 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Vorrichtung zur transdermalen Applikation von Protein- oder Peptid-Medikamenten
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5674503A (en) 1990-07-24 1997-10-07 University Of Victoria Peptides capable of eliciting an immune response to leishmaniasis and methods of using the same
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2067754C (en) 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
JPH04187640A (ja) 1990-11-22 1992-07-06 Chiba Seifun Kk 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤
US5279544A (en) * 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
US5332576A (en) 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
AU664178B2 (en) * 1991-03-19 1995-11-09 Vithal J. Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5256422A (en) 1991-03-28 1993-10-26 Micro Vesicular Systems, Inc. Lipid vesicle containing water-in-oil emulsions
DE4115849A1 (de) * 1991-05-15 1992-11-19 Lohmann Therapie Syst Lts Penetrationsfoerdernde substanz
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114346D0 (en) 1991-07-03 1991-08-21 Dow Corning Sa A method of accelerating drug permeation
US5215520A (en) * 1991-09-17 1993-06-01 Centre Internationale De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Method for delivering an active substance topically or percutaneously
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US5533995A (en) 1991-11-13 1996-07-09 Elan Corporation, Plc Passive transdermal device with controlled drug delivery
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5260066A (en) 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
US5614212A (en) * 1992-04-08 1997-03-25 International Medical Associates, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
CA2097163C (en) * 1992-06-01 2002-07-30 Marianna Foldvari Topical patch for liposomal drug delivery system
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
PT652758E (pt) * 1992-06-18 2000-04-28 Harvard College Vacinas de toxina da difteria
US5464386A (en) 1992-08-17 1995-11-07 Genetronics, Inc. Transdermal drug delivery by electroincorporation of vesicles
US5462743A (en) 1992-10-30 1995-10-31 Medipro Sciences Limited Substance transfer system for topical application
GB2273044B (en) * 1992-12-02 1997-04-09 Pacific Chem Co Ltd Medicinal patches for percutaneous administration
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ATE386800T1 (de) 1993-03-17 2008-03-15 Us Gov Health & Human Serv Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
US6010691A (en) * 1993-03-19 2000-01-04 The Regents Of The University Of California Methods for enhancing permeation of a topically administered physiologically active substance
IL109037A (en) 1993-03-19 1999-01-26 Cellegy Pharma Inc Preparations for causing phase separation of lipid layers and preparation of the above preparations
US5591601A (en) 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
EP0707465A4 (de) 1993-07-08 1997-04-16 Cygnus Therapeutic Systems Monolithisches matrix transdermales abgabesystem
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5445611A (en) 1993-12-08 1995-08-29 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal delivery with ultrasound and chemical enhancers
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6022315A (en) * 1993-12-29 2000-02-08 First Opinion Corporation Computerized medical diagnostic and treatment advice system including network access
US5533115A (en) 1994-01-31 1996-07-02 Bell Communications Research, Inc. Network-based telephone system providing coordinated voice and data delivery
ATE246909T1 (de) * 1994-03-07 2003-08-15 Theratech Inc Medikament enthaltende, adhesive, zusammenbaubare,transdermale abgabevorrichtung
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
JP4285766B2 (ja) * 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US5536263A (en) 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
IL113034A (en) * 1994-04-05 2000-02-17 Astra Ab Topical dressing
US5503843A (en) 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5733762A (en) * 1994-04-28 1998-03-31 I.D.M. Immuno-Designed Molecules Complexes of nucleic acid and polymer, their process of preparation and their use for the transfection of cells
DE4416927C1 (de) * 1994-05-13 1995-08-31 Lohmann Therapie Syst Lts Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung
SE9401921D0 (sv) 1994-06-03 1994-06-03 Sbl Vaccin Ab A method of cultivating bacteria
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5814617A (en) 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
US5505958A (en) * 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
DE69526260T2 (de) 1994-11-15 2002-10-17 Powderject Vaccines, Inc. Methode zur induktion der humoralen und zellulären immunantwort durch intrazelluläre zufuhr von peptidbeschichteten mikropartikeln
US5686100A (en) 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
ES2160727T3 (es) 1994-12-24 2001-11-16 Pacific Corp Parches medicinales para administracion percutanea.
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US5766899A (en) 1995-02-27 1998-06-16 Board Of Regents , The University Of Texas System Targeted nucleic acid delivery into liver cells
US5573778A (en) 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US5688523A (en) 1995-03-31 1997-11-18 Minnesota Mining And Manufacturing Company Method of making a pressure sensitive skin adhesive sheet material
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
AU5869796A (en) 1995-05-22 1996-12-11 Ned A. Godshall Micromechanical patch for enhancing the delivery of compound s through the skin
AU5740496A (en) * 1995-05-22 1996-12-11 General Hospital Corporation, The Micromechanical device and method for enhancing delivery of compounds through the skin
US5698416A (en) 1995-06-02 1997-12-16 The United States Of America As Represented By The Secretary Of The Army Methods for production of antigens under control of temperature-regulated promotors in enteric bacteria
US5914114A (en) * 1995-06-02 1999-06-22 The United States Of America As Represented By The Secretary Of The Army Method of raising antibodies against E. coli of the family CS4-CFA/I
US5627163A (en) * 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5637576A (en) * 1995-06-05 1997-06-10 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5840059A (en) 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
JP4338106B2 (ja) * 1995-06-07 2009-10-07 ライフ テクノロジーズ コーポレーション ペプチド増強カチオン脂質トランスフェクション
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
AU725269B2 (en) 1995-07-25 2000-10-12 Massachusetts Institute Of Technology Enhanced transdermal transport using ultrasound
ES2536459T3 (es) 1995-08-29 2015-05-25 Nitto Denko Corporation Microporación de piel humana para administración de fármacos y aplicaciones de supervisión
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5720948A (en) * 1995-11-07 1998-02-24 Helene Curtis Inc. Non-ionic surfactant emulsion vehicles and their use for deposition of drug into and across skin
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
WO1997031119A1 (en) 1996-02-21 1997-08-28 Res Inst For Genetic And Human Methods and compositions for protective and therapeutic genetic immunization
US5736154A (en) * 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
AU2593897A (en) 1996-03-22 1997-10-10 South Alabama Medical Science Foundation Molecule and method for importing dna into a nucleus
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
GB9619002D0 (en) 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
EP0921840B1 (de) 1996-07-03 2003-05-28 Altea Therapeutics Corporation Mehrfache mechanische mikroperforierung von haut oder schleimhäuten
JP2002514047A (ja) 1996-07-10 2002-05-14 イミュネックス・コーポレーション 樹状細胞を活性化する方法
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US6033684A (en) * 1996-08-28 2000-03-07 Jonor, Inc. Compositions and methods for wound management
US6365178B1 (en) * 1996-09-06 2002-04-02 Watson Pharmaceuticals, Inc. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
US5693024A (en) 1996-09-27 1997-12-02 Becton Dickinson And Company Iontophoretic drug delivery system, including method for determining hydration of patch
US5738647A (en) * 1996-09-27 1998-04-14 Becton Dickinson And Company User activated iontophoretic device and method for activating same
US5760096A (en) * 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
ES2290969T3 (es) * 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
DE19653606A1 (de) 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
WO1998029134A2 (en) 1996-12-31 1998-07-09 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
WO1998046208A1 (en) 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Hair follicle dna delivery system
JP3879785B2 (ja) 1997-05-20 2007-02-14 日東電工株式会社 キラーｔ細胞賦活剤
WO1999004009A1 (en) 1997-07-14 1999-01-28 Wisconsin Alumni Research Foundation Method of dna vaccination using dna encoding antigen and encoding il6
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
AU737717B2 (en) 1997-08-13 2001-08-30 Uab Research Foundation, The Vaccination by topical application of genetic vectors
WO1999008689A1 (en) 1997-08-21 1999-02-25 Powderject Vaccines, Inc. Mucosal immunization using particle-mediated delivery techniques
US5993852A (en) 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
EA003832B1 (ru) 1997-09-15 2003-10-30 Дженетик Иммьюнити, Ллс. Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
ES2198780T3 (es) 1997-11-20 2004-02-01 Aventis Pasteur Un metodo para administrar adn in vivo usando un aparato sin agujas.
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
US6087341A (en) 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
EP1356823B1 (de) * 1998-02-25 2013-01-02 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Verwendung von Hautpenetrationsförderern und für die Zerstörung der oberen Hautschichten geeigneten Mitteln zur Erhöhung der durch ein Adjuvant induzierten Immunantwort
BR9908278A (pt) * 1998-02-25 2002-01-02 Iomai Corp Uso de agentes de melhoria de penetração e de rompimento de barreiras da pele, melhorar a resposta transcutânea imune induzida pela etoxina de ribosilatação de adp
US6173202B1 (en) * 1998-03-06 2001-01-09 Spectrx, Inc. Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
US6022316A (en) 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications
AU3089599A (en) 1998-03-18 1999-10-11 Smithkline Beecham Corporation Production of purified mutant enterotoxin for use as an adjuvant
WO1999047164A1 (en) 1998-03-18 1999-09-23 The Administrators Of The Tulane Educational Fund Use of mutant enterotoxin with excess b-subunit as an adjuvant
US6033673A (en) 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
ATE315653T1 (de) 1998-04-22 2006-02-15 Chiron Corp Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
CA2329252A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for topical delivery of oligonucleotides
SE9801898L (sv) 1998-05-28 1999-07-05 Moelnlycke Health Care Ab Sårförband eller fixeringstejp för hud innefattande ett plastfilmsskikt belagt med en klibbig elastomer innehållande partikelformiga förankringselement
WO1999062537A1 (en) 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US6503231B1 (en) * 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
JP4275768B2 (ja) * 1998-06-18 2009-06-10 久光製薬株式会社 水性粘着膏体
US6210672B1 (en) * 1998-10-20 2001-04-03 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce Langerhans cell migration
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
ATE264098T1 (de) 1998-12-07 2004-04-15 Elan Pharma Int Ltd Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
JP2002532130A (ja) * 1998-12-18 2002-10-02 ソントラ・メディカル・インコーポレーテッド 経皮輸送の改善の方法および装置
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
AU4188100A (en) * 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
US6348212B2 (en) * 1999-05-18 2002-02-19 Lectec Corporation Treating traumatic burns or blisters of the skin
WO2000074714A2 (en) 1999-06-03 2000-12-14 Glenn Gregory M Indicators for monitoring the technique of transcutaneous immunization
DE60044084D1 (de) 1999-06-04 2010-05-12 Georgia Tech Res Inst Vorrichtungen zur vergrösserten penetration von mikronadeln in biologischen hautschichten
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6379324B1 (en) * 1999-06-09 2002-04-30 The Procter & Gamble Company Intracutaneous microneedle array apparatus
US6312612B1 (en) 1999-06-09 2001-11-06 The Procter & Gamble Company Apparatus and method for manufacturing an intracutaneous microneedle array
US6190367B1 (en) * 1999-09-22 2001-02-20 Becton, Dickinson And Company Medical site prep device
US6331266B1 (en) 1999-09-29 2001-12-18 Becton Dickinson And Company Process of making a molded device
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
AU784781B2 (en) 1999-11-10 2006-06-15 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
MXPA02010407A (es) * 2000-04-20 2003-05-23 Univ Maryland Aislamiento y caracterizacion del operante csa (etec-cs4-pili) y metodos para su uso.
EP1290451B1 (de) 2000-05-23 2005-12-07 University Of Southern California Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1
US6440096B1 (en) 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
US6656147B1 (en) 2000-07-17 2003-12-02 Becton, Dickinson And Company Method and delivery device for the transdermal administration of a substance
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
WO2002064193A2 (en) 2000-12-14 2002-08-22 Georgia Tech Research Corporation Microneedle devices and production thereof
CA2437899C (en) * 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
US20040109869A1 (en) * 2001-03-19 2004-06-10 Iomai Corporation Transcutaneous immunostimulation
US20040185055A1 (en) 2001-03-19 2004-09-23 Glenn Gregory M Transcutaneous immunostimulation
CA2447795A1 (en) * 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
US20030157159A1 (en) * 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
US6869602B2 (en) * 2002-02-20 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells
CA2477273A1 (en) * 2002-02-25 2003-09-18 U.S. Army Medical Research And Materiel Command Method of making cs6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections
US20040137004A1 (en) * 2002-03-19 2004-07-15 Glenn Gregory M Patch for transcutaneous immunization
US20060002960A1 (en) * 2003-12-09 2006-01-05 Paul Zoeteweij GM1 binding deficient exotoxins for use as immunoadjuvants
CN101242869B (zh) * 2005-09-02 2010-05-26 Iomai公司 经皮递送疫苗和透皮递送药物的装置及其应用

Also Published As

Publication number Publication date
WO2002064162A2 (en) 2002-08-22
ES2310201T3 (es) 2009-01-01
WO2002064162A3 (en) 2003-10-30
US7527802B2 (en) 2009-05-05
AU2002250071B2 (en) 2008-02-14
PT1372708E (pt) 2008-09-29
EP1372708B1 (de) 2008-06-18
JP2005504002A (ja) 2005-02-10
CA2437899A1 (en) 2002-08-22
CA2437899C (en) 2012-05-15
EP1372708A2 (de) 2004-01-02
DE60227157D1 (de) 2008-07-31
JP2010180228A (ja) 2010-08-19
US20040146534A1 (en) 2004-07-29
CY1111030T1 (el) 2015-06-11
DK1372708T3 (da) 2008-10-20

Similar Documents

Publication Publication Date Title
ATE398461T1 (de) Impstoffe zur transkutanen immunisierung gegen reisediarrhö
Ghiara et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection
CA2931146C (en) Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
Conceição et al. A recombinant chimera composed of R1 repeat region of Mycoplasma hyopneumoniae P97 adhesin with Escherichia coli heat-labile enterotoxin B subunit elicits immune response in mice
Bruxelle et al. Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile
Mirzaei et al. The study of H. pylori putative candidate factors for single-and multi-component vaccine development
KR101818901B1 (ko) 돼지흉막폐렴균의 재조합 ApxIA, ApxIIA, ApxIIIA toxin의 N 또는 C 말단 분자 및 불활화 돼지흉막폐렴균을 이용한 돼지 흉막폐렴 백신 조성물
ATE471328T1 (de) Verbindungen mit immunologischem adjuvanseffekt
Barry et al. Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains
Gohar et al. Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model
Arshadi et al. Immunogenic potency of formalin and heat inactivated E. coli O157: H7 in mouse model administered by different routes
Stasiłojć et al. Recombinant Bacillus subtilis spores elicit Th1/Th17-polarized immune response in a murine model of Helicobacter pylori vaccination
Esmaeilkhani et al. In vivo validation of the immunogenicity of recombinant baumannii acinetobactin utilization a protein (rBauA)
Marzouqi et al. Development of improved vaccines against whooping cough: current status
Lavender et al. Klebsiella pneumoniae type 3 fimbria-mediated immunity to infection in the murine model of respiratory disease
Shim et al. Efficacy of poly [di (sodium carboxylatophenoxy) phosphazene](PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens
Rezaei et al. In silico design and in vivo evaluation of two multi-epitope vaccines containing build-in adjuvant with chitosan nanoparticles against uropathogenic Escherichia coli
Schadich et al. Role of Salmonella Typhi Vi antigen and secretory systems on immune response
Lee et al. Tetanus toxin fragment C fused to flagellin makes a potent mucosal vaccine
EP2686010A2 (de) Zusammensetzungen und verfahren zur induktion von immunreaktionen gegen bakterien des genus staphylococcus
Lee et al. Vaccination and mucosal responses to Helicobacter pylori infection.
Isaka et al. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant
Holmgren et al. Oral cholera vaccines
Olivera et al. Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection
Parvane et al. Evaluation of PLGA-encapsulated recombinant GroEL of S. typhi immune responses against enterohaemorrhagic and enteropathogenic Escherichia coli

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1372708

Country of ref document: EP